Dysautonomia

A Holistic Approach to Parkinson's Disease Endpoint Data Collection: Efficacy, Safety and Quality of Life, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, April 30, 2024
Brain, Parkinson's disease, Safety, QOL, Data science, MD, Doctor of Philosophy, American Opportunity Tax Credit, Diary, QT, Pros, MPH, Medicine, PD, Quality of life, Dysautonomia

TORONTO, April 30, 2024 /PRNewswire-PRWeb/ -- In this webinar, the expert speakers will comprehensively explore Parkinson's disease endpoint data collection, where they will delve into the crucial elements of efficacy, safety and quality of life. The webinar will highlight the revolutionary Opal wearable solution and its important role in providing quantitative gait assessments, thus offering a better understanding of disease progression.

Key Points: 
  • TORONTO, April 30, 2024 /PRNewswire-PRWeb/ -- In this webinar, the expert speakers will comprehensively explore Parkinson's disease endpoint data collection, where they will delve into the crucial elements of efficacy, safety and quality of life.
  • The webinar will highlight the revolutionary Opal wearable solution and its important role in providing quantitative gait assessments, thus offering a better understanding of disease progression.
  • These circuits represent crucial targets for assessing patient eligibility, safety and therapeutic efficacy in the development of disease-modifying therapies.
  • Register for this webinar to learn about the complexities of Parkinson's disease endpoint data collection and obtain invaluable insights for improving patient outcomes and advancing therapeutic interventions.

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Retrieved on: 
Tuesday, April 23, 2024
RSRT, Neurological disorder, Health, Rett syndrome, Respiratory rate, Partnership, Research, ECG, Heart rate, Speech, Therapy, Patient, Data collection, Caregiver, Posture, Drug development, Biomarker, Genetic disorder, Sleep, Frasier, Dysautonomia, Medical device

CAMPBELL, Calif., April 23, 2024 /PRNewswire/ -- Vivalink, a leading provider of digital healthcare solutions, announces its collaboration with the Rett Syndrome Research Trust (RSRT) to advance research into Rett syndrome, a rare neurological disorder. As part of this partnership, Vivalink is providing its Multi-Vital ECG wearable technology and data services for heart rate and oxygen saturation monitoring to support RSRT's new VIBRANT study, aimed at assessing autonomic dysfunction in individuals with Rett syndrome.

Key Points: 
  • CAMPBELL, Calif., April 23, 2024 /PRNewswire/ -- Vivalink , a leading provider of digital healthcare solutions, announces its collaboration with the Rett Syndrome Research Trust (RSRT) to advance research into Rett syndrome, a rare neurological disorder.
  • Vivalink's advanced wearable devices provide an important opportunity to expedite drug development in the pursuit of a cure for Rett Syndrome.
  • "We are excited to partner with the Rett Syndrome Research Trust in their pioneering study," said Aaron Timm, Chief Commercial Officer at Vivalink.
  • "We hope to empower researchers with the tools they need to make meaningful advancements in understanding and treating Rett syndrome."

Infectious Disease Specialist Calls Campaign against Repurposed Drugs in COVID-19 a ‘Great Hypocrisy’

Retrieved on: 
Thursday, March 21, 2024
Vanderbilt University, COVID, HCQ, Rheumatoid arthritis, Infection, Azithromycin, Lupus, Diabetes, COVID-19, Patient, Knowledge, Journal, Mortality, Addiction, Hydroxychloroquine, AAPS, Dysautonomia, Physician, Ivermectin, IVM, Pharmaceutical industry

Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.

Key Points: 
  • Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.
  • “In fact, all evidence is inherently flawed.”
    Dr. Hoffman points out how inconsistencies and double standards reveal the FDA’s hypocrisy regarding HCQ and ivermectin (IVM).
  • Paxlovid, he writes, has not been shown to be effective in hospitalized COVID patients, whereas the “flawed” study of HCQ demonstrated a greater than 60 percent benefit in reducing mortality.
  • “There is in fact a corpus of knowledge about the use of HCQ, IVM, and other off-label drugs, for example, at c19hcq.org, c19IVM.org18, and earlycovidcare.org,” Dr. Hoffman states.

PMD Solutions Supports RSRT's Biosensor VIBRANT Study for Rett Syndrome with Donation of FDA-cleared RespiraSense Devices and Analytics

Retrieved on: 
Thursday, March 28, 2024
Emerald, Emory University, Doctor of Philosophy, ECG, Partnership, Respiratory rate, Heart rate, Patient, Research, Neurodevelopmental disorder, RSRT, Dysautonomia, Sleep, Artificial intelligence, Rett syndrome, Tidal volume, Radio, PMD, FDA, Movement, Pharmaceutical industry

TRUMBULL, Conn., March 28, 2024 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions, a leading provider of innovative healthcare technologies, in their upcoming biosensor validation study called VIBRANT. PMD Solutions will generously donate their state-of-the-art RespiraSense devices and advanced analytics to support RSRT's efforts in assessing autonomic dysfunction in individuals with Rett syndrome, utilizing cutting-edge digital technologies.

Key Points: 
  • PMD Solutions will generously donate their state-of-the-art RespiraSense devices and advanced analytics to support RSRT's efforts in assessing autonomic dysfunction in individuals with Rett syndrome, utilizing cutting-edge digital technologies.
  • PMD Solutions will generously donate their state-of-the-art RespiraSense devices and advanced analytics to support RSRT's efforts in assessing autonomic dysfunction in individuals with Rett syndrome, utilizing cutting-edge digital technologies.
  • The integration of RespiraSense devices with PMD Solutions' cutting-edge analytics offers a comprehensive solution for tracking and analyzing breathing parameters in Rett syndrome patients.
  • By donating RespiraSense devices and analytics for RSRT's biosensor validation study, PMD Solutions will contribute significantly to the advancement of RSRT's mission to cure Rett syndrome.

Research Team Progresses to Final Phase in NIH Competition, Pioneering Autonomic Neuromodulation to Expand Applications for Spinal Stimulation

Retrieved on: 
Thursday, March 21, 2024
Kessler Institute for Rehabilitation, Research, Blood pressure, Reward, Health, TIM, Applied Physics Laboratory, Reynolds Center, Johns Hopkins, SPARC, Learning, Caregiver, News, Rehabilitation, University, Doctor of Philosophy, MD, Quality of life, NIH, Peripheral, Kessler Foundation, Competition, Tetraplegia, Autonomic nervous system, Mobility, Safety, University of Louisville, Neurostimulation, Self-management, Dysautonomia, Bangladesh Technical Education Board, Select Medical, Common Fund for Commodities, Pharmaceutical industry

EAST HANOVER, N.J., March 21, 2024 /PRNewswire/ -- Marking significant progress towards improving the lives of individuals with spinal cord injuries, Kessler Foundation, University of Louisville, and John Hopkins Applied Physics Laboratory (with the support of Medtronic) have collaboratively won the $1,000,000 prize for Phase 2 of the Neuromod Prize for their project titled, "Neuromodulation of the lumbosacral spinal cord for improvement of autonomic function after spinal cord injury." With this win, the team advances to compete for the Phase 3 prize pool of $5 million.

Key Points: 
  • With this win, the team advances to compete for the Phase 3 prize pool of $5 million.
  • Phase 1 called for innovative therapy concepts and development plans, leading to Phase 2's proof-of-concept studies by the eight selected teams.
  • On February 27, 2024, the NIH announced the four Phase 2 victors, marking a breakthrough moment in neuromodulation research.
  • "Most importantly, what we are learning and sharing about neuromodulation through this Competition will influence new approaches to treating other types of disabling autonomic dysfunction."

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Retrieved on: 
Thursday, November 16, 2023
SEQUOIA, American Autonomic Society, Autonomic nervous system, OHQ, Orthostatic hypotension, AAS, Patient, University School, Research, Week, Noh, Neurology, Dysautonomia, Pharmaceutical industry, Medical imaging

DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.

Key Points: 
  • DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.
  • Anchor-based analyses help establish thresholds used to interpret the clinical meaningfulness of changes in patient-reported outcomes measures such as the Orthostatic Hypotension Questionnaire (OHQ).
  • This anchor-based analysis model will aid in the interpretation of clinically meaningful changes to the OHSA composite score observed in CYPRESS.
  • Further, establishment of an anchor-based, clinically meaningful change in the OHSA composite primary endpoint will be important for clinicians, regulators, and payors.

Guidance Statement for Mental Health Symptoms of Long COVID Announced by the American Academy of Physical Medicine and Rehabilitation

Retrieved on: 
Wednesday, November 8, 2023
AAPM&R, American Academy of Physical Medicine and Rehabilitation, Selective serotonin reuptake inhibitor, Rehabilitation, Physician, Prevalence, Anxiety, AAPM, Sleep, PM, R, Multimedia, Mental, Dysautonomia, PTSD, Quality of life, Injury, COVID, COVID-19, American Academy, PASC, SAMHSA, Joint, Brain, Spinal cord, Ligament, Depression, Tendon, Physical medicine and rehabilitation, PM&R, Patient, Pediatrics, Mental health, Fatigue, Nursing, Pharmaceutical industry, Medical device, Long COVID, MD

Long COVID can cause new mental health symptoms, worsen existing mental health conditions, or mimic other LC symptoms.

Key Points: 
  • Long COVID can cause new mental health symptoms, worsen existing mental health conditions, or mimic other LC symptoms.
  • Long COVID can cause new mental health symptoms and can also worsen existing mental health conditions or mimic other Long COVID symptoms.
  • "There really is some nuance in looking at the mental health symptoms of Long COVID because Long COVID symptoms that are related to mental health can also exacerbate or mimic other symptoms of Long COVID, such as fatigue, brain fog, and sleep disturbances," said Abby Cheng, MD, FAAPMR, author of the guidance.
  • Traditional nonpharmacologic and pharmacologic mental health treatments, such as SSRIs, should be considered in tandem for treating mental health symptoms of Long COVID.

Dr. Huda Zoghbi Reveals New Research Into the Mechanisms Driving Rett Syndrome at the 2023 World Congress of Neurology

Retrieved on: 
Wednesday, October 18, 2023
Spectrum, Seizure, Neuron, Behavior, Human, Genetics, MD, MECP2, DSM-IV codes, Research, WCN, Dysautonomia, Baylor College of Medicine, Disorder, Rett syndrome, Neurology, Brain, Tremor, Ataxia, MECP2 duplication syndrome, Patient, Pharmaceutical industry, Medical imaging

Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders.

Key Points: 
  • Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders.
  • Her research also pinpointed the specific neurons and circuit abnormalities that mediate the various symptoms of Rett syndrome.
  • Moreover, this breakthrough research has far-reaching implications, not only for Rett syndrome but for a broader spectrum of neuropsychiatric disorders.
  • Visit wcn-neurology.com to learn more about Dr. Zoghbi and all the featured research at this year's WCN.

Dr. Huda Zoghbi Reveals New Research Into the Mechanisms Driving Rett Syndrome at the 2023 World Congress of Neurology

Retrieved on: 
Wednesday, October 18, 2023
Spectrum, Seizure, Neuron, Behavior, Human, Genetics, MD, MECP2, DSM-IV codes, Research, WCN, Dysautonomia, Baylor College of Medicine, Disorder, Rett syndrome, Neurology, Brain, Tremor, Ataxia, MECP2 duplication syndrome, Patient, Pharmaceutical industry, Medical imaging

Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders.

Key Points: 
  • Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders.
  • Her research also pinpointed the specific neurons and circuit abnormalities that mediate the various symptoms of Rett syndrome.
  • Moreover, this breakthrough research has far-reaching implications, not only for Rett syndrome but for a broader spectrum of neuropsychiatric disorders.
  • Visit wcn-neurology.com to learn more about Dr. Zoghbi and all the featured research at this year's WCN.

CurePSP Recognizes Three Prominent Medical Institutions for Their Care for PSP, CBD and MSA

Retrieved on: 
Thursday, October 5, 2023
Diagnosis, Dysautonomia, Social, Research, Corticobasal degeneration, Rush Alzheimer's Disease Center, Patient Centered Primary Care Collaborative, Neurology, MSA, Safety, University, Baylor College of Medicine, Palsy, PSP, Education, Vanderbilt University, Movement disorder, Nursing, LCSW, Growth, Deficit spending, DSM-IV codes, CBD, Roy, Multiple system atrophy, Baylor University, Patient, Parkinson's disease, Parkinson, Pharmaceutical industry, MSW

PSP, CBD and MSA, which are considered "atypical parkinsonian syndromes," often go underrecognized and underdiagnosed.

Key Points: 
  • PSP, CBD and MSA, which are considered "atypical parkinsonian syndromes," often go underrecognized and underdiagnosed.
  • Additionally, autonomic dysfunction (e.g., blood pressure regulation, urinary control) is a hallmark feature of MSA, while PSP and CBD can present with cognitive impairment and difficulty expressing words.
  • "The continued growth of our care network is one impactful way we can work toward improving the standard of care for PSP, CBD and MSA."
  • "Through becoming a CurePSP Center of Care, our ability to care for our patients will only expand and strengthen," Dr. Brown said.